Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ketamine Plus Neurocognitive Training for Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Participants will:~1. be between the ages of 18 and 60 years,~2. have not responded to one or more adequate trials of FDA-approved antidepressants within the current depressive episode, determined by Antidepressant Treatment History Form~3. score ≥ 25 on the Montgomery Asberg Depression Rating Scale (MADRS)~4. score \>1SD above the normative mean on the Cognitive Triad Inventory self subscale \*OR\* \<1SD below the normative mean on the Rosenberg self-esteem scale~5. possess a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document~6. agree to sign a release of information (ROI), identifying another individual \[friend, family member, etc.\] as a contact person while the patient is enrolled in the study.~Exclusion Criteria:~1. Presence of lifetime bipolar, psychotic, or autism spectrum; current problematic substance use (e.g., substance use disorder); or lifetime recreational ketamine or PCP use~2. Use of a Monoamine Oxidase Inhibitor (MAOI) within the previous 2 weeks~3. Failure to meet standard MRI inclusion criteria: those who have cardiac pacemakers, neural pacemakers, cochlear implants, metal braces, or other non-MRI-compatible metal objects in their body, especially in the eye. Dental fillings do not present a problem. Plastic or removable dental appliances do not require exclusion. History of significant injury or surgery to the brain or spinal cord that would impair interpretation of results.~4. Current pregnancy or breastfeeding, or failure to engage in an effective birth control strategy throughout the duration of the study~5. Acute suicidality or other psychiatric crises requiring treatment escalation.~6. Changes made to treatment regimen within 4 weeks of baseline assessment~7. Reading level \<6th grade~8. For study entry, patients must be reasonable medical candidates for ketamine infusion, as determined by a board-certified physician co-investigator during study screening. Serious, unstable medical illnesses including respiratory \[obstructive sleep apnea, or history of difficulty with airway management during previous anesthetics\], cardiovascular \[including ischemic heart disease and uncontrolled hypertension\], and neurologic \[including history of severe head injury\] will be exclusions.~9. Clinically significant abnormal findings of laboratory parameters \[including urine toxicology screen for drugs of abuse\], physical examination, or ECG.~10. Uncontrolled or poorly controlled hypertension, as determined by a board-certified physician co-investigator's review of vitals collected during screening and any other relevant medical history/records.~11. Patients with one or more seizures without a clear and resolved etiology.~12. Patients starting hormonal treatment (e.g., estrogen) in the 3 months prior to Screening. Birth control is not an exclusion.~13. Past intolerance or hypersensitivity to ketamine or midazolam.~14. Patients taking medications with known activity at the NMDA or AMPA glutamate receptor \[e.g., riluzole, amantadine, lamotrigine, memantine, topiramate, dextromethorphan, D-cycloserine\], or the muopioid receptor.~15. Patients taking any of the following medications: St John's Wort, theophylline, tramadol, metrizamide~16. Patients who have received ECT in the past 6 months prior to Screening.~17. Patients currently receiving treatment with vagus nerve stimulation (VNS) or repetitive transcranial stimulation (rTMS).~18. Patients taking benzodiazepines (within 8 hours of infusion) or GABA agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine + Cognitive Training (Type: EXPERIMENTAL): None
- Ketamine + Sham Training (Type: SHAM_COMPARATOR): None
- Saline + Cognitive Training (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete